Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects.
- Resource Type
- Article
- Authors
- Flanagan, Shawn; Minassian, Sonia L.; Passarell, Julie A.; Fiedler ‐ Kelly, Jill; Prokocimer, Philippe
- Source
- Journal of Clinical Pharmacology. Oct2017, Vol. 57 Issue 10, p1290-1294. 5p.
- Subject
- *ANTIBIOTICS
*CLINICAL trials
*COMMUNICABLE diseases
*COMPARATIVE studies
*CONFIDENCE intervals
*CLINICAL drug trials
*HIGH performance liquid chromatography
*OBESITY
*RETROSPECTIVE studies
*RECEIVER operating characteristic curves
*DATA analysis software
*DESCRIPTIVE statistics
*PHARMACODYNAMICS
- Language
- ISSN
- 0091-2700
The article focuses on a study regarding pharmacokinetics of tedizolid, a prodrug of novel oxazolidinone tedizolid, in obese and nonobese people. It mentions that obesity is defined as body mass index (BMI) and states that it is associated with a risk factor for infection and antimicrobial treatment failure. It also mentions that tedizolid phosphate has been approved for the treatment of skin structure infections and acute bacterial skin.